EUCTR2005-006074-10-GB进行中（未招募）1 期
A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. The subject signs a written assent form and the parent/guardian signs a written informed consent form prior to the initiation of any study-related activities.
- •2. Male or female subjects aged 2 to 17 years who speak, read and write English as age appropriate and/or parent guardian
- •3. To be eligible for entry in the treatment group of the study, a female must be
- •a. Not pregnant or nursing
- •b. Of non-childbearing potential ie a pre-menarcheal female who has not yet entered puberty as evidenced by lack of breast development or who has had a hysterectomy and/or bilateral oophorectomy.
- •c. If of childbearing potential, subjects must have a negative urine pregnancy test at the screening visit, and agree to use of an acceptable method of contraception from at least the commencement of their last period prior to the first dose of study medication and to continue until the first period after treatment or after the Week 24 Follow-up visit, whichever is longest
- •4. The subject has isolated eosinophilic oesophagitis defined as:
- •Peak esophageal eosinophil counts (highest count of eosinophils per HPF in at least one of all esophageal sites biopsied) of 20 or more eosinophils in a minimum of one HPF at 400X magnification on histology of oesophageal biopsies from distal and mid-oesophagus within 2 weeks of commencing study medication.
- •Inadequate response to or intolerant of therapy for eosinophilic oesophagitis
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Current evidence of eosinophilic gastrointestinal enteropathy (EGID), other than eosinophilic oesophagitis
- •2. Current, or suspected evidence of gastroesophageal reflux disease, or other causes of oesophagitis.
- •3. Current evidence, or history of (anytime in the past):
- •a. hypereosinophilic syndromes,
- •b. allergic gastroenteritis,
- •c. bacterial infections*,
- •d. parasitic infestations*,
- •e. collagen vascular disease,
- •f. vasculitis,
- •g. allergic drug reaction,
- •h. graft-versus host disease.
- •i. chronic idiopathic inflammatory bowel disorders (ulcerative colitis, Crohn's disease, chronic granulomatous disease)
- •*If the subject has a past history of bacterial or parasite infection/infestation, the investigator must ensure that the bacterial or parasite infaction/infestation was adequately treated and/or that there is no current bacterial or parasite infection/infestation.
- •4. Current evidence, or history of celiac disease
- •5. Current evidence of active H. pylori infection.
- •6. Abnormal 12-lead ECG at Screening which is clinically significant. Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •7. Use or administration of any of the prohibited medications listed in Section 9.2 of the protocol from Screening and throughout completion of Week 34 follow-up assessments or immunisation from 6 weeks prior to Screening through the Week 24 visit. Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •8. Failure to remain on a stable dose of one (or more) permitted medication(s) for at least 1 month prior to the Screening visit and throughout completion of Week 34 follow-up assessments. Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •9. Failure to remain on stable elemental diet or dietary manipulations for at least 3 months prior to the Screening Visit and throughout completion of Week 34 follow-up assessments. Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •10. Known history of allergic reaction to previous antibody therapy.
- •11. Any previous treatment with anti-hIL-5, anti-IgE monoclonal antibody or other biological agents.
- •12. Use of an investigational drug within 30 days of entering the study. Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •13. Evidence of renal disease or serum creatinine > 1.5 times upper limit of normal range (ULN). Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •14. Evidence of hepatic disease, impairment or abnormal liver function test i.e. AST, ALT >1.5 times ULN , bilirubin >1.5 times ULN. Note that this exclusion criteria does not apply for subject who are considered for enrolment in the observational cohort
- •15. Current evidence of HIV, Hepatitis B or C infection.
- •16. History or suspicion of cu
研究者
相似试验
招募中
Unknown
A Randomized, Double-Blind, Parallel Group Clinical Study To Evaluate Efficacy And Safety Of UO ABG 01 In The Management Of Borderline Cardio Vascular Risk FactorsCTRI/2023/10/058501Xtractiva Life Science Private Limited
招募中
3 期
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant AlbendazoleOnchocerciasisPACTR202003567524647Medicines Development for Global Health12,500
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 100000004871EUCTR2021-006069-39-DESanofi-Aventis Recherche & Développement190
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-006069-39-PLSanofi-Aventis Recherche & Développement190
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Safety of Viwithan in stressed Adult healthy Humans.CTRI/2022/12/048354Vidya Herbs Pvt Ltd